Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11488631 | PMC |
| http://dx.doi.org/10.1111/pcn.13540 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Asenapine add-on treatment for schizophrenia adults who received antipsychotics: A 52-week, open-label study.
Psychiatry Clin Neurosci
June 2023
Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Japan.
Asenapine for the treatment of bipolar disorder.
Expert Opin Pharmacother
August 2019
a Dipartimento di Medicina Clinica e Sperimentale, Section of Psychiatry , University of Pisa, Pisa , Italy.
: Bipolar I disorder (BDI) is amongst the most debilitating psychiatric conditions with a great impact on both patients and their families. A class of drugs commonly used in this condition is second-generation antipsychotics (SGAs) including asenapine, one of the latest to be introduced into the clinical practice worldwide to treat manic episodes in BDI. : The aim of this paper is to critically review the literature on the pharmacological characteristics, tolerability, and safety data of asenapine, as well as on its short- and long-term clinical trials in manic episodes as both a monotherapy and as an add-on treatment.
View Article and Find Full Text PDFA Review of the Pharmacological and Clinical Profile of Newer Atypical Antipsychotics as Treatments for Bipolar Disorder: Considerations for Use in Older Patients.
Drugs Aging
October 2018
Division of Geriatric Psychiatry, McLean Hospital, Belmont, MA, USA.
Bipolar disorder prevalence rates vary in the older adult population (defined as age ≥ 65 years), ranging from 1% in community dwellers to as high as 8-10% in hospital inpatients. Although older agents, including lithium and valproic acid, offer significant antimanic efficacy, as supported by a recent randomized controlled trial (RCT), there is growing interest in using atypical antipsychotics to treat bipolar disorder in older adults. Newer atypical antipsychotics are of interest based on their tolerability and efficacy in the general adult bipolar population.
View Article and Find Full Text PDFAsenapine in the management of impulsivity and aggressiveness in bipolar disorder and comorbid borderline personality disorder: an open-label uncontrolled study.
Int Clin Psychopharmacol
May 2018
Department of Experimental and Clinical Medicine, Psychiatric Clinic University Hospital 'Gaspare Rodolico', University of Catania, Catania, Italy.
Borderline personality disorder (BPD) often co-occurres with bipolar disorder (BD). Impulsivity and aggressiveness represent core shared features and their pharmacological management is mainly based on mood stabilizers and antipsychotics, although scarce evidence is available for this context of comorbidity. The aim of the present study was to evaluate the role of Asenapine as an adjunctive drug for reducing aggressiveness and impulsivity in a sample of Italian BD type I outpatients with or without a comorbid BPD.
View Article and Find Full Text PDFA Review of Asenapine in the Treatment of Bipolar Disorder.
Clin Drug Investig
February 2018
Psychiatry Section of the Ramón y Cajal University Hospital, IRYCIS, CIBERSAM, University of Alcalá, Ctra. Colmenar Viejo, km. 9,100, 28034, Madrid, Spain.
Bipolar disorder places a significant burden on the affected individuals, their family, healthcare systems and the overall economy. More treatment options are needed, especially those with better efficacy and tolerability. Asenapine is a second-generation antipsychotic approved in Europe (brand name Sycrest) for the treatment of moderate-to-severe manic episodes associated with bipolar I disorder in adults, and in the US (brand name Saphris) for the treatment of manic or mixed episodes of bipolar I disorder in adults and children aged 10-17 years.
View Article and Find Full Text PDF